List of Excipients in Branded Drug ESTRACE

Generic Drugs Containing ESTRACE

Company	Ingredient	NDC	Excipient
Allergan Inc	estradiol	0430-0720	DIBASIC CALCIUM PHOSPHATE DIHYDRATE
Allergan Inc	estradiol	0430-0720	LACTOSE MONOHYDRATE
Allergan Inc	estradiol	0430-0720	MAGNESIUM STEARATE

What are the Most Frequently-Used Excipients in ESTRACE?

# Of NDCs	Excipient
2	CERESIN
1	DIBASIC CALCIUM PHOSPHATE DIHYDRATE
2	EDETATE DISODIUM

Estrace Excipient Strategy and Commercial Opportunities: Formulation, Generic Competition, Patents, and Market Access

Last updated: August 25, 2026

Estrace is a long-established estradiol product with limited remaining protection from composition-of-matter or product patents. Commercial opportunity is concentrated in differentiated vaginal formulations, preservative-free or low-irritation excipient systems, applicator design, dose reduction, manufacturing efficiency, and regulatory strategy. The principal product is Estrace vaginal cream, 0.01% estradiol, used for vulvar and vaginal atrophy associated with menopause. Estradiol tablets marketed under the Estrace name have a separate regulatory and commercial history.

The most defensible opportunity is not a conventional generic cream alone. It is a formulation platform that improves leakage, dose consistency, patient comfort, applicator usability, preservative exposure, or storage stability while preserving local efficacy and a commercially manageable FDA pathway.

What is Estrace and which dosage forms are commercially relevant?

Estrace is an estradiol product associated with two principal dosage forms:

Product	Active ingredient	Strength	Route	Commercial relevance
Estrace vaginal cream	Estradiol	0.01%, equivalent to 0.1 mg/g	Vaginal	Main formulation opportunity
Estrace tablets	Estradiol	Historically 0.5 mg, 1 mg, and 2 mg strengths	Oral	Mature generic market

Estrace vaginal cream is approved for treatment of moderate-to-severe symptoms of vulvar and vaginal atrophy due to menopause. The FDA label identifies each gram of cream as containing 0.1 mg of estradiol.[1]

The product is a locally administered estrogen formulation, although systemic absorption occurs. The label carries class-wide estrogen warnings relating to endometrial cancer, cardiovascular disorders, breast cancer, and probable dementia risk in applicable populations.[1]

What excipients are used in Estrace vaginal cream?

The exact excipient system is commercially important because it affects rheology, spreading, leakage, preservative exposure, microbial control, applicator compatibility, and patient tolerability.

The current U.S. prescribing information identifies the cream base as containing the following inactive ingredients:

• Cetyl palmitate
• Stearyl alcohol
• Glycerin
• Mineral oil
• Polysorbate 80
• Propylene glycol
• Purified water
• Sodium lauryl sulfate
• Methylparaben
• Propylparaben
• Titanium dioxide

The listed excipients create a semisolid emulsion or cream system with an oil phase, aqueous phase, surfactant components, humectants, and preservatives.[1]

What does each excipient contribute?

Excipient category	Estrace-related function	Strategic implication
Mineral oil	Emollient and oil-phase component	Supports spreadability but may contribute to leakage or messiness
Cetyl palmitate	Wax-like consistency agent	Influences viscosity, structure, and temperature sensitivity
Stearyl alcohol	Thickener, emollient, co-emulsifier	Can improve body but may affect sensory profile
Polysorbate 80	Emulsifier and solubilizing aid	Supports phase stability; compatibility must be assessed
Propylene glycol	Humectant and solvent	Can improve wetting but may cause irritation in sensitive users
Glycerin	Humectant	Supports hydration and cream feel
Sodium lauryl sulfate	Surfactant	May assist dispersion but creates a potential irritation concern
Methylparaben and propylparaben	Preservatives	Support microbiological stability but create preservative-free positioning opportunities
Titanium dioxide	Opacifier and colorant	Provides appearance control; removal may simplify the formulation
Purified water	Aqueous vehicle	Drives microbial-control and packaging requirements

The product’s commercial weakness is the same as its formulation opportunity: a conventional cream may be perceived as messy, may leak after administration, and may expose users to multiple excipients that can cause irritation or concern.

What excipient strategies could improve Estrace vaginal cream?

Can a preservative-free Estrace alternative gain market share?

Yes. A preservative-free formulation could target patients who experience irritation or prefer to avoid parabens. The technical challenge is microbiological control. A preservative-free aqueous or emulsion cream would require a tightly controlled manufacturing process, validated in-use stability, suitable packaging, and a container-closure system that limits repeated microbial ingress.

Potential approaches include:

1. Single-dose unit-dose applicators.
2. Metered-dose pumps with airless delivery.
3. Laminated or co-extruded tubes with low-permeability barriers.
4. Water activity reduction through an alternative vehicle.
5. Anhydrous or substantially nonaqueous systems.
6. Sterile or low-bioburden manufacturing, where justified by the product design.

A preservative-free claim has commercial value only if the product also improves comfort, dosing, or convenience. Removing preservatives without solving leakage or applicator burden may have limited market impact.

Can a low-irritation excipient system differentiate the product?

The current formulation contains propylene glycol and sodium lauryl sulfate, both of which may be scrutinized in a sensitive mucosal-use product. A reformulation could evaluate:

• Alternative nonionic surfactants.
• Lower surfactant concentration.
• Poloxamers.
• Polyoxyl or glyceride-based emulsifiers.
• Phospholipid or lecithin-based systems.
• Reduced or eliminated propylene glycol.
• Reduced or eliminated sodium lauryl sulfate.
• Physiologically compatible buffering and tonicity control.

Any change must preserve estradiol uniformity, release, content assay, impurity profile, microbial quality, and physical stability. A less irritating system could support a premium prescription product, although clinical tolerability claims would require appropriate evidence.

Can a mucoadhesive formulation compete with Estrace cream?

A mucoadhesive gel, thermoresponsive gel, tablet, insert, or ovule could improve residence time and reduce leakage. Candidate technologies include carbomers, polycarbophil, cellulose derivatives, poloxamer systems, and thiolated polymers.

The principal risks are:

• Inconsistent dose distribution.
• Excessive residence time.
• Local irritation.
• Difficulty removing residual product.
• Altered estradiol absorption.
• Compatibility problems with vaginal products or condoms.
• More complex clinical and regulatory requirements.

A mucoadhesive formulation has a stronger commercial case if it materially reduces dosing frequency or improves user experience. A simple cream-to-gel substitution may be vulnerable to rapid generic substitution unless the product has a clear clinical or patient-preference advantage.

What formulations are protected by Estrace patents?

Estrace vaginal cream is an old small-molecule product. The original estradiol compound and early dosage-form protection are no longer meaningful barriers to generic competition. The commercial opportunity therefore depends on new intellectual property rather than legacy Estrace exclusivity.

Potentially protectable subject matter includes:

• Specific excipient ratios.
• Preservative-free compositions.
• Narrow pH or osmolality ranges.
• Rheological profiles.
• Particle-size or estradiol dispersion parameters.
• Dose-uniformity specifications.
• Applicator geometry.
• Metered-dose delivery mechanisms.
• Airless packaging.
• Manufacturing processes that improve content uniformity.
• Stability profiles under accelerated or in-use conditions.
• Combination products containing estradiol and another active ingredient.

A patent directed only to routine excipient substitution may face obviousness challenges. Stronger claims would link the formulation to a demonstrated technical result, such as improved stability, reduced leakage, reduced irritation, improved dose recovery, or a defined pharmacokinetic or clinical profile.

What is the Orange Book status of Estrace?

Estrace vaginal cream is regulated as a drug-device presentation involving a semisolid drug product and an applicator. Orange Book assessment should distinguish between the reference drug product, listed patents, exclusivity, and any device-related rights.

The FDA Orange Book is the controlling source for current patent and exclusivity listings. It should be reviewed by NDA number and active listing status before relying on a particular patent position.[2]

For a mature Estrace product, the expected commercial position is:

Issue	Assessment
New chemical entity exclusivity	Expired
Original estradiol composition protection	Expired
Generic competition	Established
Biosimilar pathway	Not applicable
Remaining strategic protection	Reformulation, device, process, and method claims
Key regulatory barrier	Demonstrating equivalence for a complex semisolid
Main substitution risk	FDA-approved generic or authorized-generic cream

Generic applicants for topical and vaginal semisolid products may pursue an abbreviated new drug application. Depending on FDA product-specific guidance and the formulation, equivalence may involve comparative quality attributes, in vitro release testing, pharmacokinetic studies, clinical endpoint studies, or a combination of approaches.[3]

When does Estrace lose exclusivity?

Estrace’s core exclusivity has already expired. Estradiol is a long-established active ingredient, and the product has been exposed to generic competition for years.

The relevant commercial question is not when Estrace loses exclusivity, but whether a manufacturer can establish a differentiated product with independent protection. A new product may obtain:

• Five years of new chemical entity exclusivity only in circumstances not applicable to ordinary reformulation of estradiol.
• Three years of exclusivity for qualifying new clinical investigations supporting a change in product, indication, dosing, or formulation.
• Pediatric exclusivity if applicable.
• Patent protection for a new formulation, delivery system, manufacturing process, or method of use.

A conventional reformulation without qualifying clinical work generally does not recreate the exclusivity position of a new molecular entity.

Are there Paragraph IV challenges to Estrace?

Paragraph IV exposure is primarily relevant to listed patents that remain active and are subject to certification by an ANDA applicant. Because Estrace is a mature product with expired core protection, the principal litigation risk is likely to arise from later-listed formulation, device, or method-of-use patents rather than the original Estrace product.

A generic applicant may certify that a listed patent is invalid, unenforceable, or will not be infringed. A Paragraph IV notice can trigger patent litigation and a potential 30-month stay under the Hatch-Waxman framework, subject to statutory requirements and FDA implementation.[4]

For a new Estrace-like product, the more material risk is reverse: a reformulator may create its own patent estate, but generic applicants could challenge narrow claims covering excipient ratios or delivery components. Patent strength will depend on claim breadth, reproducibility, examples, comparative data, and whether the claimed feature produces an unexpected result.

What patent litigation and settlement issues affect Estrace?

No legacy composition-of-matter litigation should be expected to block the market. The relevant litigation categories are:

• ANDA litigation involving a later-listed formulation patent.
• Device patent disputes involving applicators or metered-dose pumps.
• Trade-secret disputes involving cream manufacturing and homogenization.
• Trademark disputes involving the Estrace name.
• Product-liability litigation related to estrogen warnings and long-term use.
• Contract or license disputes involving a reformulation platform.

Settlement agreements in the generic sector can establish an agreed launch date, but they cannot be inferred from generic availability alone. Any analysis should rely on FDA, court, SEC, or company disclosures rather than marketplace timing.

Which companies are challenging Estrace commercially?

Competition exists across several segments:

Segment	Competitive products or strategies
Generic cream	Generic estradiol vaginal cream products
Lower-dose vaginal estrogen	Estradiol vaginal inserts, tablets, and softgel products
Ring delivery	Estradiol vaginal rings
Non-estrogen alternatives	Prasterone vaginal inserts and ospemifene tablets
Branded reformulations	Lower-mess, lower-dose, or device-enabled products
Compounded products	Custom creams and suppositories, subject to compounding limitations

The closest commercial competitors are not limited to generic Estrace cream. Products that reduce administration frequency or avoid cream handling can take share even when their acquisition cost is higher.

How does Estrace compare with competing vaginal estrogen products?

Product type	Main advantage	Main weakness	Excipient opportunity
Estradiol cream	Flexible dose and broad application	Mess, leakage, applicator burden	Low-irritation, preservative-free, metered delivery
Vaginal tablet or insert	Cleaner administration	Less flexible dose adjustment	Rapid disintegration, low-residue polymers
Vaginal ring	Long dosing interval	Insertion and removal burden	Elastomer compatibility and controlled release
Softgel insert	Low-volume delivery	Device and insertion requirements	Lipid vehicle, capsule shell, stability
Prasterone insert	Non-estrogen positioning	Different active ingredient and evidence base	Moisture control and insert robustness
Ospemifene tablet	Oral administration	Systemic exposure and oral safety considerations	Conventional oral excipient optimization

Estrace cream retains an advantage in dose flexibility. A competing formulation must therefore compete on tolerability, convenience, mess reduction, or dosing frequency rather than price alone.

What FDA regulatory pathway applies to an Estrace reformulation?

A manufacturer developing a generic version should evaluate the ANDA pathway. A manufacturer developing a meaningfully different dosage form, delivery system, strength, or clinical profile may need a 505(b)(2) application.

ANDA opportunity

The ANDA route is most suitable for a product that matches the reference listed drug in dosage form, route, strength, active ingredient, and relevant quality attributes. For a complex vaginal cream, the major workstreams include:

• Qualitative and quantitative excipient characterization.
• Estradiol particle-size and dispersion control.
• Comparative physicochemical testing.
• Rheology and viscosity profiling.
• In vitro release testing.
• Microbiological quality and preservative-effectiveness testing.
• Container-closure and applicator qualification.
• Stability and in-use studies.

505(b)(2) opportunity

A 505(b)(2) product may be appropriate for:

• A novel vaginal gel.
• A controlled-release insert.
• A new strength.
• A preservative-free product supported by new clinical data.
• A new applicator or drug-device presentation.
• A formulation with materially different pharmacokinetics or local exposure.

The 505(b)(2) route can support patent and regulatory differentiation but usually requires more clinical and CMC investment than a conventional ANDA.

What manufacturing and intellectual-property barriers exist?

Estradiol is potent at low dose, making content uniformity a central manufacturing risk. The main technical barriers are:

1. Uniform dispersion of a low-dose active in a semisolid base.
2. Control of estradiol polymorphic form and particle size.
3. Prevention of phase separation during storage.
4. Consistent fill weight and dose recovery.
5. Applicator retention and delivery performance.
6. Microbial control in a multidose product.
7. Compatibility between formulation, tube, applicator, and closure.
8. Control of oxidation and impurity formation.
9. Reproducible rheology across manufacturing lots.

A manufacturing patent covering a narrow homogenization sequence may be commercially useful if it reduces variability or enables a preservative-free product. Trade secrets may be more valuable than patents for process parameters that are difficult to detect from the finished product.

What commercial opportunities exist in Estrace excipients?

The most attractive opportunities are:

Premium preservative-free vaginal estrogen

A single-dose or airless-packaged product could command a premium if it provides a credible tolerability and convenience advantage.

Low-mess, high-residence formulation

A gel, foam, insert, or structured emulsion that reduces leakage may compete against both generic cream and branded alternatives.

Metered-dose delivery

A metered applicator could improve dose consistency, reduce handling, and support a device or combination-product patent.

Lower-dose platform

A product designed for maintenance dosing could reduce total estrogen exposure and create a differentiated positioning strategy, subject to clinical validation and labeling requirements.

Excipients for vaginal drug delivery

Suppliers can target polymers, emulsifiers, lipid vehicles, capsule shells, and packaging systems that improve mucosal compatibility or residence time. The best commercial position is an excipient with a documented performance advantage in estradiol or comparable vaginal formulations.

How strong is the Estrace patent estate?

The legacy Estrace estate is commercially weak against generic entry because core exclusivity has expired. A new estate could be moderate to strong if it combines:

• Composition claims with meaningful excipient specificity.
• Device claims covering dose metering or delivery.
• Process claims that are difficult to design around.
• Data showing reduced irritation, superior stability, or improved dose recovery.
• Method-of-use claims tied to a defined dosing regimen or patient population.

A patent covering only the presence or absence of a commonly used preservative is likely to face design-around and validity pressure. A layered estate covering formulation, packaging, manufacturing, and use provides stronger negotiating leverage.

Key Takeaways

• Estrace vaginal cream is a mature estradiol product with expired core exclusivity.
• The principal commercial opportunity is reformulation, not legacy patent enforcement.
• A preservative-free, low-irritation, low-mess, or metered-dose product has the clearest differentiation path.
• The current excipient system includes mineral oil, cetyl palmitate, stearyl alcohol, glycerin, propylene glycol, polysorbate 80, sodium lauryl sulfate, parabens, titanium dioxide, and purified water.
• The ANDA pathway is suitable for close generic copies; a materially different formulation may require 505(b)(2) development.
• Biosimilar risk is not relevant because estradiol is a small molecule.
• Manufacturing control of low-dose content uniformity, rheology, microbial quality, and applicator delivery is a greater barrier than the active ingredient itself.
• A strong new patent estate should cover formulation, packaging, delivery, manufacturing, and method of use.

FAQs

Can a preservative-free Estrace cream receive separate patent protection?

Yes. Patentability would depend on claim specificity, technical effect, nonobviousness, and supporting stability or tolerability data. Removing preservatives alone may not provide a strong patent position.

Is sodium lauryl sulfate a commercial vulnerability in Estrace cream?

Potentially. Its presence can support development of a lower-irritation formulation, but any replacement must preserve emulsion stability, estradiol uniformity, release, and microbiological quality.

Can an Estrace generic use different excipients?

Yes, subject to FDA requirements for pharmaceutical equivalence, bioequivalence or other applicable equivalence standards, quality, stability, and labeling. The regulatory burden increases when excipient changes affect product performance.

Is a vaginal estradiol insert more defensible than a cream?

Often, yes. An insert can support stronger formulation and device differentiation through controlled release, dose uniformity, reduced leakage, and packaging claims. It also requires more specialized development work.

Does Estrace have biosimilar competition?

No. Estradiol is a chemically synthesized small molecule and is regulated through generic-drug pathways rather than the biosimilar pathway.

References

1. U.S. Food and Drug Administration. (2023). Estrace vaginal cream, 0.01%: Prescribing information.
2. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book.
3. U.S. Food and Drug Administration. (2022). Product-specific guidance for estradiol vaginal cream.
4. U.S. Food and Drug Administration. (2024). Abbreviated new drug application submissions: Patent certifications and 30-month stays under Hatch-Waxman.